Gastroenterology

A matched cohort study found no meaningful difference in serious or outpatient infection risk between infliximab and adalimumab in pediatric IBD.

A 2.6 million-pair Korean cohort found modest PPI/H2RA-IBD associations that vanished once sibling comparisons controlled for family factors.

About 25% of children with EoE also have joint hypermobility and orthostatic light-headedness, new Lurie Children's data show.

Outdoor meals raise the risk of food poisoning. Here's how families can keep picnics, cookouts and beach days food-safe, from coolers to grill temperatures.

A first-in-human study of 96 preterm infants shows broadband optical spectroscopy can safely distinguish NEC from healthy tissue within 2 minutes at bedside, without pain or radiation.

The FDA has accepted Takeda's supplemental application for IV vedolizumab in patients ages 2 and older with moderate-to-severe UC or Crohn's disease, with a PDUFA date set for Q1 2027.

FDA expanded approval of linaclotide for functional constipation to include children aged 2 to 5 years.

Infants with food protein–induced enterocolitis syndrome showed distinct gut microbial composition.

Children with Crohn disease had reduced microbial diversity and increased pro-inflammatory bacteria vs peers with disorders of brain-gut interaction.

Phase 3 KEPLER data showed vedolizumab achieved remission in nearly half of children with ulcerative colitis, with consistent safety and durable benefit.

GLP-1 receptor agonist use was associated with a lower risk of asthma exacerbations in adolescents with overweight or obesity.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Can you guess the diagnosis?

Fifteen infants with suspected or confirmed infant botulism and a confirmed exposure to Byheart Whole Nutrition infant formula have been reported from 12 states.

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Long-term analysis of the PEDFIC studies presented at NASPGHAN 2025 demonstrated sustained reductions in bile acids and pruritus with odevixibat in FIC1 deficiency.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

At NASPGHAN 2025, investigators presented 52-week safety data from an ongoing phase 3 trial of linaclotide, the first approved treatment for patients aged 7 and older with IBS-C.

FDA approves first irritable bowel syndrome with constipation (IBS-C) treatment, linaclotide (Linzess), for children aged 7 years and older based on pediatric and adult trial data.

A multicenter study from NASPGHAN 2025 highlights geographic and immune-driven variations in pediatric H. pylori infection across the Americas.

If approved, this UC indication would add to pediatric indications of ustekinumab for psoriasis and active psoriatic arthritis.

Decline in maternal smoking linked to fewer US newborns with gastroschisis, highlighting benefits of public health efforts.

Children diagnosed with COVID-19 gained more weight than COVID-negative peers, especially after diagnosis, during the pandemic.

Pediatricians play a crucial role in preventing early-onset colorectal cancer by promoting healthy diets and fiber intake among children.

Richard Auchus, MD, PhD, highlights data showing that crinecerfont use in children with CAH can improve metabolic outcomes.